EntryPoint Capital LLC Acquires Shares of 19,376 Electromed, Inc. $ELMD

Key Points

• EntryPoint Capital LLC has acquired a new stake in Electromed, Inc. ($ELMD), purchasing 19,376 shares valued at approximately $462,000, representing about 0.23% of the company's total shares.
• In addition to EntryPoint, several institutional investors, including Bank of America and Russell Investments, have increased their positions in Electromed recently, indicating growing interest in the stock.
• Analysts have set a consensus rating of "Strong Buy" for Electromed, with an average price target of $33.50, reflecting expectations for significant price appreciation.

EntryPoint Capital LLC purchased a new stake in shares of Electromed, Inc. (NYSE:ELMD - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 19,376 shares of the company's stock, valued at approximately $462,000. EntryPoint Capital LLC owned 0.23% of Electromed at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Russell Investments Group Ltd. purchased a new position in Electromed during the fourth quarter valued at approximately $37,000. Bank of America Corp DE grew its position in Electromed by 179.2% in the fourth quarter. Bank of America Corp DE now owns 4,004 shares of the company's stock worth $118,000 after acquiring an additional 2,570 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Electromed in the fourth quarter worth $119,000. Tower Research Capital LLC TRC lifted its stake in shares of Electromed by 426.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,055 shares of the company's stock worth $149,000 after buying an additional 4,095 shares during the last quarter. Finally, Quantbot Technologies LP lifted its stake in shares of Electromed by 57.7% in the first quarter. Quantbot Technologies LP now owns 5,301 shares of the company's stock worth $126,000 after buying an additional 1,939 shares during the last quarter. Institutional investors and hedge funds own 40.82% of the company's stock.

Analyst Upgrades and Downgrades

ELMD has been the subject of several research analyst reports. Roth Capital began coverage on shares of Electromed in a research note on Tuesday, July 22nd. They set a "buy" rating and a $29.00 target price for the company. B. Riley upgraded shares of Electromed to a "strong-buy" rating in a research report on Thursday, May 15th. Finally, Wall Street Zen cut shares of Electromed from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Strong Buy" and an average price target of $33.50.

Electromed Trading Up 4.1%

Shares of NYSE ELMD traded up $0.83 during midday trading on Tuesday, reaching $21.03. The company's stock had a trading volume of 33,788 shares, compared to its average volume of 81,716. Electromed, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $35.56. The stock has a market capitalization of $176.32 million, a price-to-earnings ratio of 28.04 and a beta of 0.38. The stock has a 50 day simple moving average of $19.64 and a 200-day simple moving average of $22.27.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.